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Abstract
Background: Mastocytosis is characterized by the accumulation of aberrant mast cells
(MC). Patients suffering from mastocytosis suffer from a wide range of symptoms due to
increased levels of MC mediators. It would therefore be of great benefit to inhibit MC
mediator release. However, to date there are few drugs available that are known to effec-
tively lower MC mediator levels. The evidence for the involvement of the janus kinase 2
(JAK2)—signal transducer and activation of transcription 5 (STAT5) signalling pathway in
MC activation is slowly accumulating. Interference with the JAK2‐STAT5 pathway might
inhibit MC mediator release. Ruxolitinib, a JAK1/JAK2 inhibitor, indeed decreases symp-
toms like pruritus and fatigue in patients with myeloproliferative neoplasms. Yet, detailed
studies on how ruxolitinib affects human mast cell activity are lacking.
Objective: To investigate the effect of JAK1/2‐inhibition with ruxolitinib in the
human mast cell lines LAD2 and HMC1.
Methods: LAD2 and HMC1 were stimulated with substance P, codeine or the calcium
ionophore A23817. The effect of ruxolitinib on mast cell degranulation (via measure-
ment of β‐hexosaminidase, histamine release and CD63 membrane expression) and IL‐
6, IL‐13, MCP‐1 and TNF‐α production was investigated. The involvement of STAT5
activation was explored using the selective STAT5 inhibitor pimozide.
Results: Ruxolitinib effectively inhibited codeine‐ and substance P‐induced degranu-
lation in a concentration‐dependent manner. Ruxolitinib also significantly inhibited
the production of IL‐6, TNF‐α and MCP‐1 as induced by A23817 and substance P.
Selective STAT5 inhibition with pimozide resulted in diminished degranulation and
inhibition of cytokine production as induced by A23817 and substance P.
Conclusions & clinical relevance: This study demonstrates that the JAK1/JAK2 inhibi-
tor ruxolitinib can inhibit MCactivity, possibly through prevention of STAT5 activation.
This renders the JAK‐STAT pathway as an interesting target for therapy to release
symptom burden in mastocytosis and many other MC mediator‐related diseases.
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1 | INTRODUCTION
Mast cell related diseases such as systemic mastocytosis or mast
cell activation syndrome often cause debilitating symptoms mainly
due to mast cell (MC)‐derived mediators.1-3 Currently, these
symptoms are treated symptomatically with histamine antagonists,
leukotriene antagonists, cromolyn acid and acetylsalicylic acid.4
However, this regime is often insufficient to reduce symptoms to
an acceptable level in the daily life of patients, especially anaphy-
laxis, gastrointestinal symptoms or flushing can greatly influence
the quality of life.5
Most recent studies on the treatment of mastocytosis focus on
the application of tyrosine kinase inhibitors (TKI) in the advanced
forms of systemic mastocytosis (SM). These inhibitors mainly act
through targeting of the KIT‐receptor to inhibit MC growth.4,6,7
Some of these TKI are only effective in MC with wild‐type KIT while
most patients with mastocytosis harbour the activating D816V KIT
mutation.8 Although newer TKI like midostaurin are also effective in
patients with the D816V KIT mutation,its use is often hampered by
gastrointestinal adverse effects.6 Whereas the search for effective
therapies for advanced mastocytosis has been going on for years, it
is recognized only recently that TKI might also be of benefit in
patients with indolent mastocytosis. The indolent subtype has an
excellent prognosis regarding survival, but patients regularly experi-
ence symptoms caused by the released MC‐mediators rather than
from actual tissue invasion by MC. Clinical experience with KIT‐tar-
geting TKI in indolent systemic mastocytosis is limited. The multi‐TKI
masitinib was found to diminish MC mediator‐related symptoms
such as fatigue and pruritus in 8‐25% of patients.9 Next to well‐
known mediators such as histamine, leukotrienes and tryptase, MC
produce numerous cytokines which are associated with constitu-
tional symptoms in mastocytosis.10-13 Therefore, medication that
inhibits the release of these MC mediators would be a valuable addi-
tion to the, currently limited, therapeutic arsenal for indolent sys-
temic mastocytosis.
Janus kinase (JAK) molecules are involved in the intracellular
transduction of signals from multiple receptors, leading to down-
stream activation of signal transducer and activation of transcription
(STAT) molecules and subsequent cellular responses.14 Of the differ-
ent JAK‐ and STAT molecules and signaling pathways currently
known, the JAK2‐STAT5 pathway is considered the most important
for growth and survival of MC.15 STAT5 also plays a role in IgE‐
mediated MC degranulation, rendering the JAK2‐STAT5 pathway an
interesting target for the inhibition of MC activation.16 In support of
this, it has previously been shown that the JAK1/JAK2 inhibitor rux-
olitinib attenuates ovalbumin‐induced passive systemic anaphylaxis
in mice, while another study demonstrated that several JAK2‐ and
STAT5‐inhibitors were able to inhibit activation of canine mastocy-
toma cell lines.17,18 Furthermore, two recent case studies of patients
with systemic mastocytosis reported that MC mediator‐related
symptoms decreased upon treatment with ruxolitinib.19,20
Although these data suggest that JAK2‐STAT5 inhibition might
effectively reduce the release of MC mediators, basal data on its
actual effect on human MC are scarce. The next step towards safe
implementation of JAK‐STAT inhibitors in the treatment of mastocy-
tosis would be to further explore their exact effects on human MC.
To investigate this, we conducted in vitro studies with ruxolitinib,
using two different human mast cell lines and several parameters of
MC activation.
2 | MATERIALS AND METHODS
2.1 | Cell culture
Two different human mast cell lines were used: HMC1 and
LAD2. HMC1 cells grow independently of stem cell factor (SCF)
as a result of an activating KIT mutation (kindly provided by dr.
Butterfield, Mayo Clinic, Rochester, Minnesota).21 DNA sequenc-
ing confirmed the presence of the G560V and D816V mutation
in KIT. LAD2 is a SCF dependent mast cell line representing
wild‐type human MC (kindly provided by drs. Kirshenbaum and
Metcalfe, National Institute of Allergy and Infectious Diseases,
Bethesda, Maryland).22
HMC1 cells were cultured in RPMI+ medium (Lonza, Verviers,
Belgium) supplemented with 10% fetal calf serum, 50 μmol/L β‐mer-
capto‐ethanol (Sigma‐Aldrich, St. Louis, Missouri), and antibiotics
(penicillin/streptomycin, Lonza). LAD2 cells were cultured in Stem
Pro‐34 medium supplemented with 2.6% nutrient supplement (both
Life Technologies, Grand Island, New York), 2 mmol/L ultraglutamine
(Lonza), 100 ng/mL SCF (R&D systems, Abbingdon, UK), and antibi-
otics (penicillin/streptomycin).
2.2 | Beta‐hexosaminidase release
MC degranulation was measured by β‐hexosaminidase assay, as
adopted from Rådinger et al.23 In brief, 2 × 104 LAD2 cells in
100 μL per condition were transferred to a 96‐well plate in calcium
free phosphate‐buffered saline (PBS). The cells were incubated for
30 minutes with varying concentrations of ruxolitinib (Apex Bio,
Houston, Texas) or the STAT5‐inhibitor pimozide (R&D systems)
before further stimulation. Cells were stimulated with 40 μg/mL of
codeine (Clinical pharmacy of Erasmus MC, Rotterdam, The Nether-
lands) or 5 μmol/L of substance P (R&D systems) for 15 minutes at
37°C. Hereafter, plates were centrifuged at 400 G for 4 minutes.
Subsequently, 50 μL of supernatant was added to 100 μL of p‐nitro-
phenyl N‐acetyl‐ β‐D‐glucosaminide (p‐NAG, Sigma‐Aldrich) in citrate
buffer (pH 4.5), while the cells were lysed by adding 150 μL 0.1%
Triton X solution (Sigma‐Aldrich). Fifty microlitres of the cell lysate
was added to 100 μL of p‐NAG in a different plate. After incubation
for 90 minutes at 37°C, the reaction was stopped by adding 100 μL
of glycine 400 mmol/L to each well. Optical density (OD) values
were measured at 405 and 620 nm using a ELISA plate reader. The
relative β‐hexosaminidase release was calculated as follows: (2x Δsu-
pernatant)/(Δsupernatant + (4*Δcell lysate)) = % β‐hexosaminidase
release. Δsupernatant = OD value supernatant—OD value blank
condition.
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2.3 | Histamine release
For the determination of histamine release, LAD2 cells were used.
The cells were incubated with varying concentrations of ruxolitinib
and subsequently stimulated with codeine for 15 minutes, according
to the protocol as described above for the β‐hexosaminidase assay.
Histamine levels in the supernatant were measured by ELISA (IBL
Solutions, Rorsachenberg, Switzerland).
2.4 | Surface membrane CD63 expression
MC degranulation is accompanied by the movement of CD63 to the
external surface of the membrane, and CD63 expression can there-
fore be used to measure MC degranulation.24 LAD2 cells were sus-
pended in PBS to a concentration of 3 × 105 cells in 500 μL per
tube. The cells were first incubated with ruxolitinib or pimozide for
30 minutes, and subsequently stimulated with codeine at a concen-
tration of 40 μg/mL for 15 minutes at 37°C. The cells were stained
with FITC‐conjugated anti‐CD63 antibody (ThermoFisher, Waltham,
Massachusets). Membrane CD63 expression was analysed on a flow-
cytometer (LSRII, Becton Dickinson, Franklin Lakes, New Jersey).
2.5 | Cytotoxicity assay
Cytotoxicity of ruxolitinib and pimozide was tested by several meth-
ods. Firstly, HMC1 and LAD2 cells were cultured for up to 24 hours
in the presence of varying concentrations of ruxolitinib (from
50 nmol/L to 50 μmol/L) and pimozide (2 ‐100 μmol/L). The cells
were assessed by microscopy and trypane blue exclusion. Secondly,
LDH levels in supernatant of cell cultures of 24 hours were
measured by a standard colorimetric assay kit (Roche, Basel,
Switzerland).
2.6 | Cytokine production
For the measurement of cytokine and chemokine production, HMC1
cells were seeded in a 96‐well plate at 2 × 105 cells in 200 μL cul-
ture medium per condition. Subsequently, the cells were incubated
for 30 minutes with ruxolitinib (or pimozide) before stimulating them
with 1 μmol/L of A23187 or 5 μmol/L of substance P. After testing
several time periods of stimulation ranging between 6 and 24 hours
for the optimal duration, TNF‐α levels in the supernatant were mea-
sured after 6 hours of stimulation, and MCP‐1 and IL‐6 levels were
measured after 24 hours of stimulation. See the results section for
further details. Cytokines were measured by ELISA (all R&D systems,
except for IL‐6 which was from ThermoFisher). The choice of cytoki-
nes was based on previous research on cytokine levels in patients
with mastocytosis and other myeloproliferative diseases.25-27
2.7 | Statistical analysis
Graphpad Prism 5 (San Diego, California) was used to analyse most
data except for the flow cytometry data, for which FlowJo (Ashland,
Oregon) was used. One‐way Analysis of Variance (ANOVA) and sub-
sequent Dunnett post‐hoc tests were used to determine the statisti-
cal significance between the ruxolitinib‐ or pimozide‐treated
conditions and the positive control conditions. IC50 values were cal-
culated for the inhibitory effects on degranulation and cytokine pro-
duction of both compounds. The results of β‐hexosaminidase,
histamine and cytokines/chemokine measurements are depicted in
bar graphs as mean values with standard error of the mean (SE).
CD63 expression is depicted in histograms as mean fluorescent
intensity.
3 | RESULTS
3.1 | Compound control
Ruxolitinib was not cytotoxic to either HMC1 as LAD2 cells up to a
concentration of 50 μmol/L as determined by microscopy, trypane
blue exclusion and by LDH release assay for up to 48 hours of incu-
bation. Pimozide was cytotoxic to both cell lines from a concentra-
tion of 50 μmol/L and higher as determined by LDH release assay.
The vehicle, DMSO, did not affect degranulation up to a concentra-
tion of 5%, as measured by β‐hexosaminidase release and CD63
expression (data not shown).
3.2 | Degranulation
First, titration of the stimuli was performed to find the optimal dura-
tion and concentration of stimulation for the β‐hexosaminidase assay
(Figure S1) and flow cytometry (Figure S2). HMC1 cells appeared
unsuitable for these degranulation assays because their degranula-
tion could not be further enhanced by stimulation with codeine, as
measured by β‐hexosaminidase release (Figure S3). For HMC1 cells,
there also was no significant upregulation of CD63 expression upon
stimulation with codeine (data not shown). Therefore, only LAD2
cells were used for all degranulation assays. Optimal concentrations
to stimulate degranulation were 40 μg/mL for codeine, and 5 μmol/L
for substance P, for a duration of 15 minutes.
Ruxolitinib effectively inhibited substance P‐ and codeine‐
induced degranulation of LAD2 cells, in a concentration‐dependent
manner reaching statistical significance at 50 and 10 μmol/L,
(P: 0.028 and P: 0.006, respectively; Figure 1A,B). This corresponded
to an IC50 of 7.9 μmol/L (95% CI 2.3‐27.3) for substance P‐induced
degranulation, and an IC50 of 10 μmol/L (95% CI; 8.9‐12.6) for
codeine‐induced degranulation. Ruxolitinib also inhibited codeine‐
induced histamine release and CD63 expression of LAD2 cells, how-
ever, without reaching statistical significance (Figure 1C and D,
respectively).
3.3 | Cytokine and chemokine production
HMC1 cells were used for all experiments performed to evaluate
cytokine and chemokine production. First, experiments were per-
formed to determine which substance and duration of stimulation
HERMANS ET AL. | 3
was optimal for the induction of IL‐6, TNF‐ α, MCP‐1 and IL‐13 pro-
duction in HMC1 cells. This revealed that the optimal stimulation
time to induce production of IL‐6 and MCP‐1 was 24 hours, and that
a stimulation time of 6 hours was optimal for TNF‐α. This trend was
seen regardless of which stimulus was used. A23187 was more
potent stimulus for IL‐6 and TNF‐α production, whereas Substance P
was the best stimulus for MCP‐1 production (summarized in Fig-
ure 2A). Since the IL‐13 production was low, regardless of the stimu-
lus used, this was not further pursued. Codeine did not induce the
production of detectable levels of any of the tested cytokines.
Ruxolitinib effectively inhibited the production of IL‐6, TNF‐α,
and MCP‐1 by HMC1 cells in a concentration‐dependent manner
(Figure 2B‐D). For IL‐6 production, a statistically significant effect
was reached at 500 nmol/L of ruxolitinib and higher (P: 0.047 for
500 nmol/L compared with positive control). For TNF‐α, the highest
level of ruxolitinib (50 μmol/L) displayed significant inhibition
(P: 0.038). MCP‐1 production was significantly inhibited by
ruxolitinib 5 μmol/L and higher (P: 0.021). The IC50 for the inhibition
of IL‐6 production by ruxolitinib was 7.6 μmol/L (95% CI 6.0‐9.7),
and the IC50 for the inhibition of TNF‐α production was 1.3 μmol/L
(95% CI 0.2‐9.1). The IC50 for MCP‐1 production was 4.1 μmol/L,
however with a wide 95% CI (0.4‐43).
3.4 | Pimozide
To determine the contribution of STAT5 to MC degranulation and
cytokine production, we investigated the effect of pimozide, a selec-
tive STAT5 inhibitor. Pimozide partly inhibited substance P‐ and
codeine‐induced degranulation of LAD2 cells in a concentration‐
dependent manner, however, the obtained decrease in beta‐hexosa-
minidase release was not statistically significant (Figure 3). Pimozide
had more potent inhibitory effect on cytokine production by HMC1
cells. The A23187 induced production of IL‐6 and TNF‐ α by HMC1
cells was already significantly reduced at the lowest concentration of
pimozide of 5 μmol/L (P: 0.002 and P: 0.029, respectively, Figure 4A,
B). Similarly, the substance P‐induced MCP‐1 production was also
inhibited, reaching statistical significance at a concentration of
20 μmol/L (P: 0.002; Figure 4C). Of note, the spontaneous
F IGURE 1 The Effect of Ruxolitinib on Degranulation of LAD2 Cells, as Measured by Beta‐Hexosaminidase Release, CD63 Expression and
Histamine Release. Legend: Ruxolitinib effectively inhibits degranulation of LAD2 cells in a dose‐dependent manner. A, Beta‐hexosaminidase
assay for substance P induced degranulation. Concentration of Substance P: 5 μmol/l. B, Beta‐hexosaminidase assay for codeine induced
degranulation. Concentration of codeine: 40 μg/mL. C, Inhibition of histamine release after stimulation with codeine 40 μg/mL. D, Inhibition of
CD63 expression after stimulation with codeine 40 μg/mL. MFI = mean fluorescent intensity. *P < 0.05 and #P < 0.01 as compared with
positive control. All bars are depicting the mean of 3 repeated experiments with SE
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production of MCP‐1 appeared to be relatively high in repeated
experiments. The IC50 for the inhibition of IL‐6 production by pimo-
zide was 7.4 μmol/L (95% CI 3.1‐17.9), the IC50 for TNF‐α produc-
tion by pimozide was 8.0 μmol/L (95% CI 3.7‐17.1). The IC50 for
MCP‐1 production was 13.9 μmol/L (95% CI 7.1‐27.2).
4 | DISCUSSION
Here, we provide evidence that the JAK1/JAK2 inhibitor ruxolitinib
can efficiently inhibit MC degranulation as well as the production of
cytokines. Since substance P and codeine are ligands for G‐protein
coupled receptors (GPCRs),28,29 this work implies a link between the
JAK2‐STAT5 pathway and GPCRs. These stimuli were chosen
because it is well‐known that codeine can cause MC degranulation,
as is confirmed by the fact that many patients with mastocytosis
experience MC mediator related symptoms after ingestion of
codeine.30 However, since codeine is an exogenous stimulus, we
repeated most experiments with substance P and/or A23187.
In our study, ruxolitinib clearly inhibited MC activity, but its exact
intracellular mechanism is not fully elucidated yet. JAK2, and subse-
quently STAT5, are situated downstream of KIT in MC,16 and
thereby involved in the proliferation and survival of MC.15 The
involvement of the JAK2‐STAT5 pathway in MC degranulation is less
well‐described, although there is some evidence available. The role
of STAT5 in IgE‐mediated MC degranulation has been investigated
by several groups, and it is now accepted that STAT5 is activated
downstream of FcεR1.16,31,32 In line with this, previous work has
proven that JAK2 is involved in IgE‐mediated leukotriene production
in mice.33 Our current data confirm the role of JAK1 and/or JAK2 in
MC degranulation and even more so in cytokine and chemokine pro-
duction. We also found that selective inhibition of STAT5 with pimo-
zide inhibited MC activity, although this did not reach statistical
significance for degranulation. Nevertheless, our data support the
theory that STAT5 is important for MC activation, although possibly
in a lesser extent than JAK2.
Substance P and codeine are ligands to GPCRs.28,29 Ruxolitinib
and pimozide both effectively blocked MC activation as induced by
F IGURE 2 The Effect of Ruxolitinib on Cytokine and Chemokine Production by HMC1 Cells. Legend: After establishing the effect of
A23187, codeine and substance P on the production of various cytokines and the cytokine MCP‐1 (A), experiments were performed with the
optimal stimulus for each cytokine. Incubation with ruxolitinib lead to decreased production of IL‐6 (B) and TNF‐α (C) after stimulation with
A23187 for 24 or 6 hours, respectively. The production of MCP‐1 after stimulation with substance P for 24 hours was also inhibited (D).
*P < 0.05 and #P < 0.01 as compared with positive control. All bars are depicting the mean of 3 repeated experiments with SE
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these stimuli. These points at a role for JAK2‐STAT5 signalling in
GPCR‐mediated MC activation. Associations between GPCRs and
JAK2‐STAT5 signalling have been described in other hematopoietic
cell types, for instance for the C‐C motif chemokine receptor 5
expressed by T‐cells and the platelet activating factor receptor
expressed by monocytic cells34,35 But to our knowledge, our study is
F IGURE 3 The Effect of Pimozide on Degranulation of LAD2 Cells. Legend: As measured by beta‐hexosaminidase release assay, pimozide
partly inhibits degranulation of LAD2 in a dose‐dependent manner. This effect was similar for stimulation with substance P 5 μmol/L (A) and
codeine 40 μg/mL (B). All bars are depicting the mean of 3 repeated experiments with SE
F IGURE 4 The Effect of Pimozide on Cytokine and Chemokine Production by HMC1 Cells. Legend: Incubation with pimozide lead to
decreased production of IL‐6 (A) and TNF‐α (B) after stimulation with A23187 for 24 or 6 hours, respectively. The production of MCP‐1 after
stimulation with substance P for 24 hours was also inhibited (C). * P < 0.05, and ** P < 0.001 as compared with positive control. All bars are
depicting the mean of 3 repeated experiments with SE
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the first to suggest an association between GPCRs and a JAK‐STAT
pathway in MC.
The most important signaling pathway downstream of GPCRs
involves phosphoinositide 3‐kinase (PI3K), which is a versatile tyro-
sine kinase that can integrate signals from different receptors.36-38
There is some evidence for crosstalk between PI3K and STAT5,
specifically in neoplastic MC.39,40 Possibly, JAK1/JAK2 inhibition by
ruxolitinib ultimately interferes with the crosstalk between PI3K and
STAT5, although this hypothesis obviously needs further testing.
Ruxolitinib is a rather specific inhibitor of JAK1 and JAK2, yet at
high concentrations it is known to inhibit JAK3 as well.41,42 The IC50
of ruxolitinib for JAK3 inhibition was reported to be
438 + 243 nmol/L in an in vitro model for myeloproliferative neo-
plasms (MPN), which was ~150‐200 times higher than the IC50 for
JAK1 or JAK2 inhibition.41 The IC50 values for ruxolitinib are much
higher in MC: they ranged between 1.3 and 10 μmol/L in our study.
These values are comparable to a study that investigated the effect
of ruxolitinib on murine MC.17 Since higher concentrations of ruxoli-
tinib are necessary to inhibit MC activation compared with the inhi-
bition of myeloid progrenitor cells, it cannot be formally excluded
that the observed effect of ruxolitinib on MC also involves inhibition
of JAK3 activity.
Regardless of any (exogenous) stimuli, neoplastic MC constitu-
tively exhibit high levels of phosphorylated STAT5.43 Additional
evidence for the continuous auto‐activation of MC in patients
with mastocytosis comes from the elevated levels of MC media-
tors at random measurements in blood and urine of these
patients.11,12,44 The inhibition of the release and/or production of
various MC mediators can potentially reduce debilitating symptoms
including pruritus, flushing, diarrhea and anaphylaxis, thereby
improving the quality of life of these patients. Excessive MC activ-
ity also plays a role in many other diseases, including mast cell
activation syndrome, chronic spontaneous urticaria, allergies and
fibrotic disease.45,46 The reduction of MC mediator levels via the
inhibition of JAK‐STAT signaling might therefore be of therapeutic
interest for these diseases as well.
Ruxolitinib is currently only approved for the treatment of the
classical myeloproliferative neoplasms (MPN). In patients with MPN,
treatment with ruxolitinib leads to a reduction of daily symptoms like
abdominal discomfort, pruritus and fatigue.47,48 In line with our find-
ings, the COMFORT‐II trial showed a decrease in the levels of IL6,
TNF‐α and VEGF in patients with MPN that were treated with rux-
olitinib.49 Given the increased number and activity of MC in bone
marrow of patients with MPN it was hypothesized that ruxolitinib
exerted its beneficial effect in MPN by inhibition of MC mediator
release/production.50,51 This hypothesis is corroborated by our cur-
rent study that indeed demonstrates an overall inhibiting effect of
ruxolitinib on MC activity. In line with this, two recent case studies
showed a convincing decrease in MC mediator related symptoms in
systemic mastocytosis upon ruxolitinib treatment19,20
Based on our data, combined with other available (pre‐)clinical
evidence as discussed above, JAK1/JAK2‐STAT5 inhibition might
represent a promising new therapeutic strategy for patients with
mastocytosis and many other MC mediator related diseases. Ulti-
mately, randomized clinical trials are necessary.
5 | CONCLUSION
We have demonstrated that the JAK1/2 inhibitor ruxolitinib effec-
tively attenuates degranulation and cytokine production by human
MC. The fact that pimozide also partly inhibited degranulation, and
substantially inhibited cytokine production, suggests a role for
STAT5 in MC activation. JAK2‐STAT5 inhibition thus emerges as a
new, highly effective, method to lower MC mediator levels. Ruxoli-
tinib, and JAK‐STAT inhibition in general, are interesting therapeutic
options to reduce debilitating symptoms in mastocytosis and a wide
range of other MC mediator‐related diseases such as mast cell
activation syndrome, chronic spontaneous urticaria and even fibrotic
disease.
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